The Safety Profile of Generic Tadalafil Products

Stay on track with Rx alerts & expert care
Side Effects and Safety
Comparing Drug Interactions
The Pharmacy
The Science Behind Tadalafil
Comparing Which Works Faster

Parameter	Brand Cialis	Generic Tadalafil
Half-Life (hours)	17.5	17.5
Absorption Time (hours)	2	2
Food Interaction	Yes (high-fat meal reduces absorption)	Yes

Such an event may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition and a cause of decreased vision, including permanent loss of vision.

Patent laws protect branded Cialis until they expire, enabling generics afterward.
The efficacy and safety of generic Cialis are supported by extensive research.
Patients with prescriptions can often opt for generic Cialis for savings.
Regulations ensure that generic Cialis must be therapeutically equivalent to original.

Physicians should consider whether their patients with underlying NAION risk factors could be adversely affected by use of PDE5 inhibitors.

Stay on track with Rx alerts & expert care

Alpha-blockers and Antihypertensives: Physicians should discuss with patients the potential for tadalafil to augment the blood-pressure-lowering effect of alpha-blockers and antihypertensive medications. Caution is advised when PDE5 inhibitors are coadministered with alpha-blockers. PDE5 inhibitors, including tadalafil, and alpha-adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. In some patients, concomitant use of these two drug classes can lower blood pressure significantly, which may lead to symptomatic hypotension (e.g., fainting).

Will Cialis help me keep an erection after ejaculating?

Renal Impairment: Creatinine clearance less than 30 mL/min or on hemodialysis: Tadalafil tablets for daily use is not recommended; tadalafil tablets for use as needed—5 mg not more than once every 72 hours. Creatinine clearance 30 to 50 mL/min: For tadalafil cialis without prescription in canada tablets for daily use treatment of BPH or ED/BPH, start dosing at 2.5 mg and increase to 5 mg based upon individual response. Tadalafil tablets for use as needed, start dosing at 5 mg not more than once per day with a maximum dose of 10 mg not more than once every 48 hours. Hepatic Impairment: In patients with mild or moderate hepatic impairment, the dose of tadalafil should not exceed 10 mg. Because of insufficient information in patients with severe hepatic impairment, use of tadalafil in this group is not recommended. Individuals who have already experienced NAION are at increased risk of NAION recurrence. PDE5 inhibitors, including tadalafil, should be used with caution in these patients and only when the anticipated benefits outweigh the risks. Individuals with “crowded” optic disc are also considered at greater risk for NAION compared to the general population. Patients with known hereditary degenerative retinal disorders, including retinitis pigmentosa, were not included in the clinical trials, and use in these patients is not recommended. Sudden Hearing Loss: Sudden decrease or loss in hearing, sometimes with tinnitus and dizziness has also been reported in men taking PDE5 inhibitors, including tadalafil. It is not possible to determine whether these hearing events are related directly to the use of PDE5 inhibitors or to other factors.

Product	Dosage	Quantity + Bonus	Price
Cialis Black	80mg	90 + 6 Pills	207.88€ 197.98€
Cialis Generic	20mg	360 + 10 Pills	427.34€ 406.99€
Cialis Generic	10mg	360 + 10 Pills	388.49€ 369.99€
Cialis Soft Tabs	20mg	120 + 6 Pills	248.64€ 236.80€
Cialis Generic	10mg	60 + 6 Pills	105.81€ 100.77€
Cialis Professional	40mg	60 + 2 Pills	262.32€ 249.83€
Cialis Generic	10mg	120 + 6 Pills	178.49€ 169.99€
Cialis Soft Tabs	20mg	30 + 4 Pills	87.43€ 83.27€
Cialis Black	80mg	10 Pills	43.27€ 41.21€
Cialis Generic	20mg	20 Pills	54.72€ 52.11€
Cialis Professional	40mg	30 Pills	148.94€ 141.85€
Cialis Original	20mg	12 Pills	78.32€ 74.59€
Cialis Original	20mg	76 + 4 Pills	319.19€ 303.99€
Cialis Generic	60mg	30 + 2 Pills	85.33€ 81.27€
Cialis Generic	5mg	120 + 6 Pills	132.92€ 126.59€
Cialis Generic	2.5mg	60 + 4 Pills	83.43€ 79.46€

Side Effects and Safety

Counseling Patients About Sexually Transmitted Diseases: The use of tadalafil offers no protection against sexually transmitted diseases. Counseling patients about the protective measures necessary to guard against sexually transmitted diseases, including Human Immunodeficiency Virus (HIV) should be considered. Consideration of Other Urological Conditions Prior to Initiating Treatment for BPH: Prior to initiating treatment with tadalafil for BPH, consideration should be given to other urological conditions that may cause similar symptoms. In addition, prostate cancer and BPH may coexist. Common Adverse Reactions: The most common adverse reactions reported in clinical trials (≥ 2%) were headache, flushing, dyspepsia, nasal congestion, back pain, myalgia, pain in limb, naspharyngitis, upper respiratory tract infection, cough, diarrhea, urinary tract infection, gastroesophageal reflux disease, abdominal pain, gastroenteritis, and hypertension.

Side effects and risks

For more information, please see accompanying Full Prescribing Information. A copy may be requested from Teva US Medical Information at 888-4-TEVA-USA (888-838-2872) or druginfo@tevapharm.com, or Teva’s Public Relations or Investor Relations contacts. Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global leader in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory. We deliver high-quality generic products and medicines in nearly every soft cialis therapeutic area to address unmet patient needs. Caution is advised when PDE5 inhibitors are coadministered with alpha-blockers.

Comparing Drug Interactions

PDE5 inhibitors, including tadalafil, and alpha-adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. In some patients, concomitant use of these two drug classes can lower blood pressure significantly, which may lead to symptomatic hypotension (e.g., fainting).

The Pharmacy

Tadalafil for once daily use has not been extensively evaluated in patients with mild or moderate hepatic impairment. Therefore, caution is advised if tadalafil for once daily use is prescribed to these patients. Because of insufficient information in patients with severe hepatic impairment, use of tadalafil in this group is not recommended. Alcohol: Physicians should inform patients that substantial consumption of alcohol (e.g., 5 units or greater) in combination with tadalafil can increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache. Concomitant Use of Potent Inhibitors of Cytochrome P450 3A4 (CYP3A4): For patients taking potent inhibitors of CYP3A4 such as ritonavir, ketoconazole, and itraconazole, the dose of tadalafil tablets should be limited to 10 mg no more than once every 72 hours.

Are you currently using Tadalafil (Cialis, Adcirca, and others)?

If once daily use is prescribed the maximum recommended dose is 2.5 mg. Combination With Other PDE5 Inhibitors or Erectile Dysfunction Therapies: The safety and efficacy of combinations of tadalafil and other PDE5 inhibitors or treatments for erectile dysfunction have not been studied. Inform patients not to take tadalafil with other 10 mg cialis PDE5 inhibitors, including ADCIRCA®. Effects on Bleeding: Tadalafil has not been administered to patients with bleeding disorders or significant active peptic ulceration. Although tadalafil has not been shown to increase bleeding times in healthy subjects, use in patients with bleeding disorders or significant active peptic ulceration should be based upon a careful risk-benefit assessment and caution. Renal Impairment: Creatinine clearance less than 30 mL/min or on hemodialysis: Tadalafil tablets for daily use is not recommended; tadalafil tablets for use as needed—5 mg not more than once every 72 hours. Creatinine clearance 30 to 50 mL/min: For tadalafil cialis without prescription in canada tablets for daily use treatment of BPH or ED/BPH, start dosing at 2.5 mg and increase to 5 mg based upon individual response. Tadalafil tablets for use as needed, start dosing at 5 mg not more than once per day with a maximum dose of 10 mg not more than once every 48 hours. Hepatic Impairment: In patients with mild or moderate hepatic impairment, the dose of tadalafil should not exceed 10 mg. Because of insufficient information in patients with severe hepatic impairment, use of tadalafil in this group is not recommended. Tadalafil for once daily use has not been extensively evaluated in patients with mild or moderate hepatic impairment. Therefore, caution is advised if tadalafil for once daily use is prescribed to these patients. Because of insufficient information in patients with severe hepatic impairment, use of tadalafil in this group is not recommended. Alcohol: Physicians should inform patients that substantial consumption of alcohol (e.g., 5 units or greater) in combination with tadalafil can increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache. Concomitant Use of Potent Inhibitors of Cytochrome P450 3A4 (CYP3A4): For patients taking potent inhibitors of CYP3A4 such as ritonavir, ketoconazole, and itraconazole, the dose of tadalafil tablets should be limited to 10 mg no more than once every 72 hours. If once daily use is prescribed the maximum recommended dose is 2.5 mg. Combination With Other PDE5 Inhibitors or Erectile Dysfunction Therapies: The safety and efficacy of combinations of tadalafil and other PDE5 inhibitors or treatments for erectile dysfunction have not been studied. Inform patients not to take tadalafil with other 10 mg cialis PDE5 inhibitors, including ADCIRCA®.

The Science Behind Tadalafil

Tadalafil should be used with caution in patients who have conditions that might predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia), or in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie’s disease). Effects on the Eye: Physicians should advise patients to stop use of all PDE5 inhibitors, including tadalafil, and seek medical attention in the event of a sudden loss of vision in one or both eyes. Such an event may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition and a cause of decreased vision, including permanent loss of vision. Physicians should consider whether their patients with underlying NAION risk factors could be adversely affected by use of PDE5 inhibitors. Individuals who have already experienced NAION are at increased risk of NAION recurrence.

Why Should I Pay More For the Same Results?

PDE5 inhibitors, including tadalafil, should be used with caution in these patients and only when the anticipated benefits outweigh the risks. Individuals with “crowded” optic disc are also considered at greater risk for NAION compared to the general population. Patients with known hereditary degenerative retinal disorders, including retinitis pigmentosa, were not included in the clinical trials, and use in these patients is not recommended. Sudden Hearing Loss: Sudden decrease or loss in hearing, sometimes with tinnitus and dizziness has also been reported in men taking PDE5 inhibitors, including tadalafil. It is not possible to determine whether these hearing events are related directly to the use of PDE5 inhibitors or to other factors. Effects on Bleeding: Tadalafil has not been administered to patients with bleeding disorders or significant active peptic ulceration. Although tadalafil has not been shown to increase bleeding times in healthy subjects, use in patients with bleeding disorders or significant active peptic ulceration should be based upon a careful risk-benefit assessment and caution.

Comparing Which Works Faster

We have an established presence in generics, specialty, OTC and API, building on more than a century-old legacy, with a fully integrated R&D function, strong operational base and global infrastructure and scale. We strive to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, we employ 45,000 professionals, committed to improving the lives of millions of patients. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Teva's tadalafil tablets, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: The uncertainty of the commercial success of our generic version of tadalafil, including due to a potential launch of an Authorized Generic version; our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; competition for our specialty products, especially COPAXONE®, our leading medicine, which faces competition from existing and potential additional generic versions and orally-administered alternatives; competition from companies with greater resources and capabilities; efforts of pharmaceutical companies to limit the use of generics including through legislation and regulations; consolidation of our customer base and commercial alliances among our customers; the increase in the number of competitors targeting generic opportunities and seeking U.S.

More FAQ

market exclusivity for generic versions of significant products; price erosion relating to our products, both from competing products and increased regulation; delays in launches of new products and our ability to achieve expected results from investments in our product pipeline; our ability to take advantage of high-value opportunities; the difficulty and expense of obtaining licenses to proprietary technologies; and the effectiveness of our patents and other measures to protect our intellectual property rights; our substantially increased indebtedness and significantly decreased cash on hand, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us; our business and operations in general, including: failure to effectively execute the restructuring plan announced in December 2017; uncertainties related to, and failure to achieve, the potential benefits and success of our new senior management team and organizational structure; harm to our pipeline of future products due to the ongoing review of our R&D programs; our ability to develop and commercialize additional pharmaceutical products; potential additional adverse consequences following our resolution with the U.S. government of our FCPA investigation; compliance with sanctions and other trade control laws; manufacturing or quality control problems, which may damage our reputation for quality production and require costly remediation; interruptions in our supply chain; disruptions of our or third party information technology systems or breaches of our data security; the failure to recruit or retain key personnel; variations in intellectual property laws that may adversely affect our ability to manufacture our products; challenges associated with conducting business globally, including adverse effects of political or economic instability, major hostilities or terrorism; significant sales to a limited number of customers in our U.S. Counseling Patients About Sexually Transmitted Diseases: The use of tadalafil offers no protection against sexually transmitted diseases. Counseling patients about the protective measures necessary to guard against sexually transmitted diseases, including Human Immunodeficiency Virus (HIV) should be considered. Consideration of Other Urological Conditions Prior to Initiating Treatment for BPH: Prior to initiating treatment with tadalafil for BPH, consideration should be given to other urological conditions that may cause similar symptoms. In addition, prostate cancer and BPH may coexist. Common Adverse Reactions: The most common adverse reactions reported in clinical trials (≥ 2%) were headache, flushing, dyspepsia, nasal congestion, back pain, myalgia, pain in limb, naspharyngitis, upper respiratory tract infection, cough, diarrhea, urinary tract infection, gastroesophageal reflux disease, abdominal pain, gastroenteritis, and hypertension. For more information, please see accompanying Full Prescribing Information. A copy may be requested from Teva US Medical Information at 888-4-TEVA-USA (888-838-2872) or druginfo@tevapharm.com, or Teva’s Public Relations or Investor Relations contacts. Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global leader in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory. We deliver high-quality generic products and medicines in nearly every soft cialis therapeutic area to address unmet patient needs. We have an established presence in generics, specialty, OTC and API, building on more than a century-old legacy, with a fully integrated R&D function, strong operational base and global infrastructure and scale. We strive to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, we employ 45,000 professionals, committed to improving the lives of millions of patients. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Teva's tadalafil tablets, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements.

Generic Cialis contains the same active ingredient, tadalafil, as brand-name Cialis.
Generic versions are usually less expensive than the brand-name medication.
FDA approved generic Cialis must meet strict manufacturing standards.
Many pharmacies offer generic Cialis options for ED treatment.

Important factors that could cause or contribute to such differences include risks relating to: The uncertainty of the commercial success of our generic version of tadalafil, including due to a potential launch of an Authorized Generic version; our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; competition for our specialty products, especially COPAXONE®, our leading medicine, which faces competition from existing and potential additional generic versions and orally-administered alternatives; competition from companies with greater resources and capabilities; efforts of pharmaceutical companies to limit the use of generics including through legislation and regulations; consolidation of our customer base and commercial alliances among our customers; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; price erosion relating to our products, both from competing products and increased regulation; delays in launches of new products and our ability to achieve expected results from investments in our product pipeline; our ability to take advantage of high-value opportunities; the difficulty and expense of obtaining licenses to proprietary technologies; and the effectiveness of our patents and other measures to protect our intellectual property rights; our substantially increased indebtedness and significantly decreased cash on hand, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us; our business and operations in general, including: failure to effectively execute the restructuring plan announced in December 2017; uncertainties related to, and failure to achieve, the potential benefits and success of our new senior management team and organizational structure; harm to our pipeline of future products due to the ongoing review of our R&D programs; our ability to develop and commercialize additional pharmaceutical products; potential additional adverse consequences following our resolution with the U.S.

Many countries have approved generic Cialis for sale in local markets.
The FDA requires generic Cialis to have the same strength, quality, and purity.
Switching between brand-name and generic Cialis should be done with medical advice.
The availability of generic Cialis has increased worldwide access to ED treatment.

government of our FCPA investigation; compliance with sanctions and other trade control laws; manufacturing or quality control problems, which may damage our reputation for quality production and require costly remediation; interruptions in our supply chain; disruptions of our or third party information technology systems or breaches of our data security; the failure to recruit or retain key personnel; variations in intellectual property laws that may adversely affect our ability to manufacture our products; challenges associated with conducting business globally, including adverse effects of political or economic instability, major hostilities or terrorism; significant sales to a limited number of customers in our U.S.

Product Type	Active Ingredient	Dosage Forms	Typical Dosage Range
Brand Cialis (Pill)	Tadalafil	5 mg, 10 mg, 20 mg	5-20 mg
Generic Cialis (Pill)	Tadalafil	2.5 mg, 5 mg, 10 mg	2.5-20 mg
Tadalafil (Bulk Powder)	Tadalafil	N/A	Varies